Alpesh Patel, MD
Interventional Pain Medicine · Baton Rouge, LANPI 1326092610
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 270 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional pain medicine clinicians in LA, where the typical reported total is $4,761.
Across 270 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$1K
- Valinor Pharma, LLC$887
- Pfizer$383
- Scilex Pharmaceuticals Inc.$274
- AbbVie$227
- Novartis$209
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,476100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 52 | $1,015 |
| Valinor Pharma, LLC | 54 | $887 |
| Pfizer | 27 | $383 |
| Scilex Pharmaceuticals Inc. | 13 | $274 |
| AbbVie(2 entities) | 17 | $227 |
| Novartis | 15 | $209 |
| Biohaven Pharmaceuticals, Inc. | 16 | $177 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $175 |
| AstraZeneca | 7 | $131 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $112 |
| Saluda Medical Americas, Inc. | 1 | $88 |
| Arbor Pharmaceuticals, Inc. | 7 | $88 |
| Teva Pharmaceuticals USA, Inc. | 5 | $83 |
| Redhill Biopharma Inc. | 4 | $83 |
| Biotronik NRO, Inc. | 2 | $70 |
| MDD US Operations, LLC | 4 | $63 |
| Assertio Therapeutics, Inc. | 4 | $56 |
| Boston Scientific | 3 | $49 |
| Si-bone, Inc. | 1 | $38 |
| Sentynl Therapeutics, Inc. | 2 | $25 |
| Nalu Medical, Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Vertex | 1 | $17 |
| Virtus Pharmaceuticals LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
How this compares
$4,483 in reported general payments places this provider in the 40th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12,192 | $302,084 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 7,577 | $223,395 |
| MovantikNaloxegol Oxalate | 426 | $182,585 |
| PercocetOxycodone Hcl/Acetaminophen | 15 | $63,192 |
| Nurtec OdtRimegepant Sulfate | 40 | $54,905 |
| Gabapentin | 3,425 | $54,321 |
| LinzessLinaclotide | 79 | $45,169 |
| Oxycodone Hcl | 2,086 | $36,291 |
| Cyclobenzaprine Hcl | 2,040 | $25,849 |
| Tizanidine Hcl | 1,789 | $24,058 |
| Diclofenac Sodium | 375 | $23,154 |
| Xtampza ErOxycodone Myristate | 51 | $22,983 |
| Lidocaine | 257 | $22,345 |
| Morphine Sulfate ErMorphine Sulfate | 1,000 | $21,870 |
| Pregabalin | 833 | $14,888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $83 | $182,585426 claims |
| PfizerNurtec Odt, Lyrica | $383 | $67,32058 claims |
| AbbVieLinzess | $227 | $45,16979 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $1,015 | $37,13468 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 57 interventional pain medicine providers in Louisiana.
Other interventional pain medicine in Baton Rouge
- Adam CarinciBaton Rouge$17K
- Jihad JihaBaton Rouge$17K
- Kelly BoussertBaton Rouge$9K
- Gary McDanielBaton Rouge$9K
- John BraswellBaton Rouge$8K
- Sean GrahamBaton Rouge$5K
- John CrosbyBaton Rouge$5K
- Joseph TurnipseedBaton Rouge$4K
- Allison WalkerBaton Rouge$2K
- John BurdineBaton Rouge$177
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.